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Introduction
Breast cancer is a heterogeneous disease, including sub  types 
based on hormone receptor status and ampliﬁ    cation of 
HER2 [1,2]. Th  ese subtypes have distinct under  lying 
molecular defects that aﬀ  ect both their aggressive  ness 
and the signaling pathways that are vulnerable to targeted 
therapies [3,4]. While these designations are extremely 
useful, breast cancer also can exhibit signiﬁ  cant intra-
tumoral heterogeneity, both between individual tumor 
cells and also between tumor and stromal compartments. 
For example, tumors classiﬁ   ed as hormone receptor 
positive may have diﬀ   erent proportions of estrogen 
receptor (ER) or progesterone receptor (PR) positive 
cells. Th   us, there may exist within a tumor some cells that 
are more versus less responsive to a given treatment, or 
cells that are more likely than others to spread distantly. 
Contributing to this intratumoral heterogeneity is the 
concept of breast cancer stem cells, which may be more 
resistant to therapies and/or more likely to metastasize 
[5,6]. In addition, breast cancer is also ‘temporally 
heterogeneous’, with cancers presenting at diﬀ  erent 
stages of their evolution. In general, cancers detected 
early in progression are less dangerous and more 
amenable to treatment than those detected later.
Characterizing the nature of an individual breast 
cancer, both in terms of type of breast cancer and stage of 
progression, is crucial for estimating prognosis of the 
patient and for the prediction that a given treatment will 
be successful. However, prognostic and predictive infor-
mation is population-based. While useful, this informa-
tion does not necessarily predict the fate of an individual 
with breast cancer. As a result, some women may be 
over-treated and others under-treated, or treated with 
therapy that will not oﬀ  er beneﬁ  t. Th   us, improved ways 
to ‘individualize’ prognosis and treatment decisions are 
needed [7].
As an attempt to meet this need for more ‘personalized’ 
information to guide treatment, additional ways are being 
studied to classify individual tumors, based on single 
biomarkers or more complex molecular signatures. 
Rapidly evolving technologies that enable detailed mole-
cular proﬁ  ling of tumors are raising hopes that breast 
cancer treatment decisions may become even more 
tailored to an individual breast cancer patient’s tumor. 
Here we discuss the role that some of these new proﬁ  ling 
approaches may play in cancer patient management, and 
the role that tumor and patient heterogeneity may play in 
using this information to best beneﬁ  t patients.
Th  e prognosis, prediction and treatment of breast 
cancer are complicated by the diverse constellation of 
causative alterations within multiple biological pathways 
that lead to this heterogeneous disease. Initial strategies 
to treat breast cancer have therefore employed gene-
speciﬁ  c,  tissue-speciﬁ   c as well as whole genome 
approaches to identify speciﬁ  c signatures related to par-
ticular breast cancer types, which can then be exploited 
to optimize treatment targeting a speciﬁ  c  patient’s 
tumors. Some studies have evaluated the expression 
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© 2011 BioMed Central Ltdstatus of individual candidate genes in cell lines and/or 
tumor material in a tissue-speciﬁ  c manner. For example, 
signiﬁ  cantly reduced levels of mRNA expression of the 
metastasis suppressor genes BRMS1, KISS1 (kisspeptin), 
KAI1 ( CD82) and Mkk4 ( MAP2K4; mitogen-activated 
protein kinase kinase 4) have been shown in breast 
cancer brain metastasis [8], with speciﬁ  c suppression of 
BRMS1 modifying several metastasis-related phenotypes 
[9]. Whole genome approaches using microarray plat-
forms have identiﬁ  ed more extensive gene sets that can 
predict a short interval to distant metastases (that is, a 
poor prognosis signature) [10,11] or have identiﬁ  ed gene 
sets that mediate metastasis from a speciﬁ  c  primary 
tissue to a tissue-speciﬁ  c host site [12,13]. Minn and co-
workers [14] identiﬁ  ed a complex 54-gene breast cancer 
set that marks and mediates breast cancer metastasis to 
the lungs and appeared to consist of at least two separate 
classes of genes that confer both breast tumorigenicity 
and lung metastagenicity, as well as one that is advan-
tageous to cells in that lung environment. Additionally, 
Kang and co-workers [15] identiﬁ   ed a functionally 
diverse gene set that, when overexpressed, cooperatively 
promotes the metastasis of breast cancer cells to bone. 
Importantly, clinically signiﬁ   cant 21-gene [16] and 
70-gene signatures [10,17] have formed the basis for 
widely used molecular diagnostic tests that have been 
translated and validated as eﬀ   ective clinical tools as 
prognostic and predictive markers for eﬀ  ective treatment 
decisions in speciﬁ  c breast cancer patient cohorts. Th  ese 
particular markers will be discussed in detail later in this 
review. Finally, several reports have addressed the contri-
butions of altered epigenetic signatures in breast cancer 
models [18,19] and through the integration of multiple 
genetic and epigenetic multi-gene platforms [20].
Th   ese reports underscore the complexity of metastasis 
as a multigenic process and support the concept that 
hetero  geneous, selectable subpopulations of cells in the 
primary tumor may possess speciﬁ  c gene sets that are 
permissive for metastasis and/or for the colonization and 
growth of those cells at speciﬁ   c secondary sites. Th  e 
challenge for the clinician remains in identifying the 
relevant gene sets and to exploit this information to 
permit better prognosis and personalized treatment 
options for individual patients.
Current prognostic and predictive factors - 
a clinical perspective
Traditional clinical prognostic factors are still commonly 
used to guide therapy. Pathologic subtyping is important. 
For example, pure inﬁ  ltrating lobular [21], phylloides [22], 
mucinous and tubular carcinomas [23] have a generally 
better prognosis than inﬁ  ltrating ductal cancers, although 
the lobular cancers may have more late relapses. Increased 
nodal status, high tumor grade, high Ki67, increased 
tumor size and negative receptor status (especially PR) are 
associated with a poorer prognosis [24]. Th   e increased use 
of sentinel lymph node dissection and subsequent more 
detailed examination of fewer nodes have resulted in more 
nodes with micrometastases (>0.2 to ≤2.0 mm), resulting 
in a new category for nodal status in the American Joint 
Committee on Cancer (AJCC) Cancer Staging Manual 
[25]. Although micro  meta  stases have been associated with 
a poorer prog    nosis [26], it is possible that their prognostic 
impact has been diluted or eliminated by the use of 
modern systemic therapy [27]. More recent classiﬁ  cations 
include HER2 status [28] and basal-like breast cancer [3]. 
Interestingly, the National Comprehensive Cancer Net  work 
(NCCN) and American Society for Clinical Oncology 
(ASCO) guidelines give discordant recommen  dations for 
use of HER2 status for prognosis [29,30]. Basal breast 
cancer is generally thought to have a poorer short-term 
but better long-term prognosis [31], but understanding of 
this variant is hampered by the absence of a universally 
accep ted  deﬁ   nition [3,32]. Th  ere is increasing evidence 
that prognosis also may be related to patient-speciﬁ  c 
factors, including very young age [33] and postmenopausal 
women who are overweight and have excessive alcohol 
consumption [34,35]. Th  us, environ  mental factors may 
have a role in determining recurrence of cancer. Although 
race has been associated with poorer prognosis [36,37], 
this might be an epiphenomenon related to a complex 
interplay between socio-economic, cultural and biologi  cal 
factors [38]. Th  erefore, a better understanding of tumor 
biology may help discriminate among the relative impor-
tance of these factors. Research on prognostic markers 
would be more clinically relevant in the future if the 
REMARK (Reporting Recommendations for Tumor Marker 
Prognostic Studies) reporting recom  men  dations for tumor 
marker studies developed by the National Cancer 
Institute-European Organisation for Research and 
Treatment of Cancer (NCI-EORTC) were imple  men  ted 
[39]. However, a recent sampling of 50 studies from high 
impact journals indicated poor compliance with the 
recom  mendations [40]. Th   ese guidelines apply not only to 
single biomarkers, but also to panels of markers and 
proﬁ  les [41].
Guidelines for the use of predictive factors to target 
therapy have been published by the St Gallen’s group 
[42], the National Comprehensive Cancer Network [29] 
and ASCO [30]. Th   e Adjuvant! Online decision aid [43], 
although widely used, does not incorporate HER2 status 
and suﬀ  ers from diﬃ   culties in interpretation of the co-
morbidity index, which may signiﬁ  cantly impact on the 
interpretation of beneﬁ  t when compared to overall and 
not just cancer mortality risks. It also does not incor-
porate potentially important independent risk factors, 
such as presence of lymphatic or vascular invasion in 
node negative disease [43,44].
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whether to give chemotherapy to postmenopausal 
women who have low or even intermediate grade ER or 
PR positive, HER2 negative breast cancers with one to 
three nodes positive or those with negative nodes and 
ER or PR positive, HER2 negative intermediate grade 
tumors [45,46]. Th  ere may also be subsets of women, 
especially those with HER2+ T1bN0 cancers, who might 
be at increased risk of relapse but for whom, at this 
time, there are no clear guidelines for treatment. 
Neoadjuvant chemo  therapy is increasingly used both in 
clinical and research settings. Although pathologic 
complete res  ponse is an important surrogate endpoint, 
more useful functional and molecular imaging tools 
along with biological assessment of tissue are required 
[47]. It is in these areas where there is the greatest 
potential for the use of newer biologically derived 
proﬁ  ling technologies. Finally, a greater understanding 
of molecular subtypes may allow for more rational use 
of chemotherapy in impor  tant subsets of breast cancers 
[48].
Molecular subtyping provides a ‘snapshot’ of a tumor at 
a single point in time. However, tumor status may change 
when metastases are compared to primary cancers. A 
meta-analysis of 8 observational studies totaling 658 
paired ER samples and 418 paired PR samples comparing 
primary and metastatic tumors showed discordance rates 
of 29% and 27% for ER and PR, respectively [49]. Informa-
tion on HER2 status when primary and metastatic sites 
were compared has given discordance rates between 0% 
and 13.6% in seven studies, suggesting somewhat higher 
concordance [50-52], although one other study had a 34% 
discordance rate [53]. Discordance in markers led to a 
change in management in 20% of patients, suggesting 
that repeat biopsies should be considered in patients with 
metastases [54]. Discordance in HER2 status also has 
been reported between primary tumors and bone 
marrow metastases [55] as well as circulating tumor cells 
[56,57], raising questions about treatment decisions 
based solely on the HER2 status of the primary tumor. 
Much remains to be learned about molecular alterations 
and gene expression patterns in primary tumors versus 
their metastases, but these studies are complicated by the 
frequent diﬃ   culty of obtaining matched tissue samples, 
especially when metastases may be detected long after a 
primary tumor has been resected. However, recent 
studies are beginning to document this heterogeneity 
[58-60]. How much these changes are driven by treat-
ment, tumor progression, discrepancies in initial typing 
or intrinsic heterogeneity is unclear. It is clear that use of 
prognostic and predictive information obtained from the 
initial diagnosis of breast cancer and resection of the 
primary tumor may be imperfect in guiding treatment of 
metastatic disease.
‘First-generation’ expression profi  ling as 
prognostic and predictive factors
As noted above, a small number of expression proﬁ  ling 
strategies have been successfully developed and validated 
for clinical use, some of which are now commercially 
available [61,62]. Th  ese include the 70-gene expression 
signature as used in the MammaPrint® (Agendia, 
Amsterdam, Th  e Netherlands) assay, and the 21-gene 
proﬁ   le used in the Oncotype Dx® (Genomic Health, 
Redwood City, CA, USA) assay. Clinical evidence in 
hormone responsive breast cancer supports the abilities of 
these assays to distinguish between patients who will do 
well and do not beneﬁ   t from chemotherapy added to 
hormone therapy, and patients who have poorer prognosis 
and who will beneﬁ  t from added chemotherapy [61,62]. 
Th   ese assays are becoming increasingly used in the clinical 
setting to help in treatment decisions. A comparison of 
four studies from the US and the Netherlands indicated 
that these assays led to changes in treatment decisions in 
18 to 44% of cases, and often in the direction of not giving 
chemotherapy to patients predicted not to beneﬁ  t. 
However, it should be noted that a recent study by Parisi 
and colleagues [63], which compared protein levels of 14 
markers used in the Oncotype Dx assay with nodal status, 
tumor size, nuclear grade and age, found that a combined 
model incor  pora  ting both molecular and standard clinical-
pathological information provided better prognostic 
information than either system alone. Th  ere thus remain 
questions about the most eﬀ   ective use of molecularly 
based assays in the clinical setting.
Some of these questions will be addressed in two 
ongoing clinical trials, MINDACT (Microarray In Node 
negative Disease may Avoid ChemoTh  erapy)  and 
TAILORx (Trial Assigning IndividuaLized Options for 
Treatment (Rx)). Both trials are designed to assess the 
abilities of molecularly based assays to determine best 
adjuvant treatment for speciﬁ  c subsets of breast cancers, 
and in particular to determine which patients need 
chemotherapy and which are unlikely to beneﬁ  t  from 
chemotherapy. Details of these trials have been 
summarized in detail elsewhere [61,62,64].
Th   e TAILORx trial is using the Oncotype Dx 21 gene 
assay, in lymph node negative, ER and/or PR positive, and 
HER2-negative tumors [62,65]. Women with low ‘recur-
rence scores’ (RS <11) will receive hormone treatment 
only, and women with high RS (>25) will receive chemo-
therapy plus hormone therapy, as current standard of 
care. Women with intermediate RS (11 to 25), where 
there is uncertainty about need for chemotherapy, will be 
randomized to hormone therapy, plus or minus 
chemotherapy, to test the beneﬁ  t of adding chemotherapy 
for this group of patients.
Th  e MINDACT trial will use the 70-gene proﬁ  le 
(MammaPrint), from fresh tissue from women with node 
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assay with current clinical-pathological assessment, as 
deﬁ   ned by the Adjuvant! Online tool [66,67]. Women 
whose risk assessments are concordant using the two 
assays will receive current standard treatment for their 
risk groups. Women with discordant determinations 
from MammaPrint versus Adjuvant! Online will be 
randomized to receive either chemotherapy or no 
chemo  therapy. Together, the MINDACT and TAILORx 
trials will provide prospective evidence about the utility 
of molecularly based tests, to help determine the need for 
adjuvant chemotherapy in some women and identify 
women who are unlikely to beneﬁ  t from chemotherapy, 
thus providing more individualized treatment decisions 
for women with breast cancer [61,62,64].
Figure 1 diagrams the path from traditional clinical and 
prognostic factors, as well as currently available and 
evolving signatures, to clinical application for improved 
and more personalized treatment decisions, as exempli-
ﬁ  ed by the examples discussed above.
The road ahead - challenges and opportunities
Th  e advent of next generation sequencing (NGS) tech-
nolo  gies promises to provide powerful new tools to 
identify those individuals who may be at risk of develop-
ing primary or metastatic tumors, and has the potential 
to further enhance ‘personalized’ treatment decisions. 
NGS allows complete genomes to be sequenced in a 
matter of days, resulting in valuable, personalized 
information identifying mutations in patient or tumor 
DNA or RNA samples. While a full review of the tech-
nologies available today is beyond the scope of this work, 
readers are directed to excellent reviews that have been 
written on the subject [68,69].
A recent report [60] demonstrated how NGS can be 
used to characterize somatic mutations occurring during 
the development and progression of lobular breast 
cancer. Using DNA and RNA resequencing, 32 somatic 
non-synonymous mutations in a metastatic tumor were 
found, 19 of which were not present in the primary 
lesion. In addition, RNA sequencing detected two new 
RNA editing events that recode the amino acid sequences 
of two proteins, SRP9 and COG3. Th  ese compelling 
results demonstrate that heterogeneity at the single 
nucleotide level can be an inherent property in low to 
intermediate grade tumors, and that signiﬁ  cant evolution 
can occur with progression of the disease.
In the clinical setting, testing of inherited loss of function 
mutations to tumor suppressor genes in women with a 
family history of breast or ovarian cancer is generally 
limited to the BRCA1 and BRCA2 genes. To address the 
fact that there are many other inherited mutations that 
may predispose one to these cancers, a recent report [70] 
developed an NGS assay to capture, sequence and detect 
all mutations in 21 genes (including BRCA1 and BRCA2) 
in women previously diagnosed with breast or ovarian 
cancer and carrying a mutation in at least one of the genes 
responsible for inherited predisposition of these diseases. 
Th   ey were able to detect all single nucleotide substitutions, 
indel mutations, and large duplications and deletions that 
had been previously conﬁ  rmed, with no false positive calls. 
Taken together, their approach showed that widespread 
genetic testing and personalized risk assessment in these 
patients is feasible.
Th   e use of massively parallel sequencing technologies, 
however, is not without signiﬁ  cant challenges that will 
have to be overcome if they are to be used extensively in 
the clinical setting. Th  e foremost of these is that the 
Figure 1. Correlating molecular and clinical characteristics can address the multiple aspects of biological, clonal and patient 
heterogeneity in breast cancer metastasis and lead to gene profi  les, commercial assays and clinical trials that ultimately result in clinical 
applications to improve prognostic accuracy and treatment outcome for individual patients.
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clinical use. At present, ten-fold coverage of an individ-
ual’s genome (about 30 Gbases) costs approximately 
US$15,000 [69], although, as the technologies evolve, it is 
expected that this cost will drop signiﬁ  cantly, as was seen 
with microarray analyses. Indeed, the National Human 
Genome Research Institute in the US has announced a 
program with the ultimate goal to completely resequence 
the human genome for $1,000 or less [60,71]. Secondly, 
the samples will rarely be purely tumor tissue, with the 
presence of ‘contaminating’ DNA or RNA derived from 
normal tissue, immune cells or stromal tissue making the 
acquisition of a ‘true’ tumor signature a challenge. 
Th   irdly, an inherent issue in NGS is the sheer volume of 
data generated by these analyses and whether appropriate 
bio  informatics expertise is available to assess these vast 
datasets.
To date, no large scale studies analogous to those that 
led to the Oncotype Dx or MammaPrint assays have been 
performed using NGS technologies. However, eﬀ  orts are 
underway to create a comprehensive database of genetic 
alterations in breast cancer, such as that being undertaken 
by the Breast Cancer International Cancer Genome 
Consortium [69,72]. Coupled with eﬀ  orts to create a panel 
of ‘normal’ samples (for example, the 1000 Genomes 
Project [73]), these initiatives have the potential to allow a 
panel of disease-speciﬁ   c genetic anomalies that may 
eventually be used in elucidating a ‘genomic alteration 
signature’. Th   ese signatures may one day be tested in large 
scale clinical trials similar to the MINDACT or TAILORx 
studies referred to earlier. In addition, as the technologies 
and associated analyses are perfected, NGS information 
may be integrated with global gene expression studies on 
a personalized basis, allowing for a comprehensive and 
reﬁ  ned prognostic ability and treatment plan.
Challenges posed by heterogeneity
Perhaps the greatest challenge to successfully develop 
clinically valid gene signatures for breast cancer diag-
nosis, prognosis and prediction of treatment res  ponse 
relates to the multiple concepts of heterogeneity of breast 
cancer. Th   ese exist at the level of the causative molecular 
pathway(s), with regard to the clonal composition of the 
tumor itself and in the context of genetic variability 
within the patient population. Tumor development is 
essentially Darwinian, in that any of a number of 
molecular pathways that have been selected for in a 
speciﬁ   c tumor cell can contribute to the ‘successful’ 
meta  static tumor [74]. Moreover, this heterogeneity is 
dynamic, as selective pressures change (that is, in the 
new environment encountered by a metastatic cell in a 
secondary tissue site) [75,76]. Th   us, gene signatures may 
oﬀ  er no more than a snapshot of a tumor’s gene expres-
sion proﬁ  le that is best relevant for only a particular point 
in time. Furthermore, the presence of subpopulations of 
tumor cells that diﬀ  er in their genetic makeup, metastatic 
potential, invasiveness and capacity to replicate may 
further compromise an already complex signature, in that 
the most clinically relevant signature may be masked by a 
‘non-lethal’ signature that dominates the tumor’s DNA or 
RNA sample. Lastly, the selection and fate of speciﬁ  c 
tumor cells and the susceptibility of these cells to appro-
priate treatments is also likely dependent on inherited 
genetic variations that can aﬀ  ect the patient’s tumor and 
response to chemotherapy [77,78]. Taken together, these 
multiple aspects of biological, clonal and patient hetero-
geneity make the process of establishing gene signatures 
both challenging and complex. Th  us, comprehensive 
genomic analysis of tumor subpopulations and of the 
host patient is likely the best way to eﬀ  ectively use gene 
signatures from both patient and tumor, so that treatment 
plans can be optimized.
Conclusion
Signiﬁ  cant progress has been made over the past decade 
that has utilized the technical advances in molecular 
genetics to develop clinically relevant tools to aid in the 
prediction and treatment of breast cancer. However, 
even as these advances have been made, we are learning 
more about the complex biology that underwrites this 
complex set of potentially devastating diseases. Several 
important challenges must be faced. First, it is clear that 
there will be no shortage of information available 
regarding clinical characteristics of the patient (that is, 
age, menopausal status) or the clinical and molecular 
characteristic of her/his tumor (ranging from tumor 
histology to genomic signatures). Instead, the clear 
challenge is to be able to capture the clinically relevant 
signature(s) from the cacophony of molecular noise that 
exists, due to inherent issues related to tumor 
heterogeneity and disease complexity. In addition, these 
individual data sets must be linked directly with 
informative patient/tumor infor  mation that is speciﬁ  c 
to that individual. Th   e selection advantage provided by 
a particular set of genetic changes is critically important 
to the survivability of that tumor cell, and ultimately 
that same set of information is critical in guiding the 
choice of an eﬀ  ective treatment regime for that patient. 
As we move forward it is therefore necessary to link 
together these new genetic signatures with speciﬁ  c 
patient subgroups, while concurrently developing the 
molecular therapies that target the speciﬁ  c  disease-
related genetic alterations identiﬁ  ed in those signatures.
This article is part of a review series on Multiple gene prognostic 
factors, edited by Lewis Chodosh.
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